Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05065736 · ClinicalTrials.gov registry record · Early Phase 1
Using a PET Imaging Agent, 18F-Clofarabine (CFA), to Measure Deoxycytidine Kinase Activity in Metastatic Cancer
A Early Phase 1 study of Metastatic Cancer and Carcinoma, sponsored by Roberto Vargas.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 4
- Enrollment target
- 1
- Study location
NCT05065736 is a Early Phase 1 study of Metastatic Cancer and Carcinoma that is actively recruiting participants, run by Roberto Vargas. The registered enrollment target is 4 participants, below the 444-participant average among 109 other Metastatic Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05065736, a Early Phase 1 study of Metastatic Cancer and Carcinoma, is actively recruiting participants, sponsored by Roberto Vargas.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 4 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate whether a new type of imaging study, called 18F-Clofarabine (CFA) PET/CT, can be used to image cancer pyrimidine metabolism in participants. PET (positron emission tomography) imaging is a way of looking at cancers that can reveal cancer metabolism. Presently, however, there are no imaging agents in routine use to look at an aspect of cancer metabolism (pyrimidine metabolism) that dictates whether certain cancer drugs, e.g., gemcitabine, are likely to be taken into the cancer cells. This clinical trial will be testing whether 18F-Clofarabine (CFA) could be an imaging agent to measure this aspect of cancer metabolism.
Conditions Studied
Interventions
- DRUG 18F-Clofarabine
Study Locations (1)
Ohio
- Cleveland Clinic, Case Comprehensive Cancer Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2023-03-06 |
| Est. Completion | 2026-06 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05065736
The ClinicalTrials.gov registry entry for NCT05065736 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 444-participant average among 109 other Metastatic Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Roberto Vargas, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Metastatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which 18F-Clofarabine is the first listed.
NCT05065736 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT05065736 about?
NCT05065736 is a clinical study titled "Using a PET Imaging Agent, 18F-Clofarabine (CFA), to Measure Deoxycytidine Kinase Activity in Metastatic Cancer". The purpose of this study is to evaluate whether a new type of imaging study, called 18F-Clofarabine (CFA) PET/CT, can be used to image cancer pyrimidine metabolism in participants. PET (positron emission tomography) imaging is a way of looking at cancers that can reveal cancer metabolism. Presentl...
What is the current status of trial NCT05065736?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 4 participants. The study started on 2023-03-06. Estimated completion is 2026-06.
What conditions does trial NCT05065736 study?
This clinical trial studies the following conditions: Metastatic Cancer, Carcinoma, Adenocarcinoma.
What interventions are being tested in trial NCT05065736?
The interventions under investigation include: 18F-Clofarabine (DRUG).
Who is sponsoring clinical trial NCT05065736?
This trial is sponsored by Roberto Vargas, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05065736 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Novel Method for Treating Lung Met w/Combo of Electric Fields & Rad Therapy: A Single-Arm
COMPLETED · Early Phase 1
-
Evaluating Disparities in Precision Oncology
RECRUITING
-
First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
RECRUITING · Phase 1
-
A Study of Reduced-dose Radiation in People With Metastatic Tumors With a Genetic Change
RECRUITING · Phase 2
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.